- £161.26bn
- £179.84bn
- $54.07bn
- 86
- 16
- 74
- 64
Annual balance sheet for AstraZeneca, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Cash | |||||
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 7,992 | 6,398 | 6,405 | 5,962 | 5,654 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 5,651 | 8,795 | 9,923 | 11,935 | 13,094 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 19,544 | 26,244 | 22,593 | 25,054 | 25,827 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 8,917 | 10,171 | 9,449 | 10,502 | 11,647 |
Net Goodwill | |||||
Net Intangible Assets | |||||
Long Term Investments | |||||
Long Term Notes Receivable | |||||
Other Long Term Assets | |||||
Total Assets | 66,729 | 105,363 | 96,483 | 101,119 | 104,035 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 20,307 | 22,594 | 26,293 | 30,542 | 27,866 |
Long Term Debt | |||||
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Deferred Income Tax | |||||
Minority Interest | |||||
Total Other Liabilities | |||||
Total Funded Status | |||||
Total Liabilities | 51,107 | 66,095 | 59,446 | 61,976 | 63,249 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Total Equity | 15,622 | 39,268 | 37,037 | 39,143 | 40,786 |
Total Liabilities & Shareholders' Equity | 66,729 | 105,363 | 96,483 | 101,119 | 104,035 |
Total Common Shares Outstanding |